Provided by Tiger Trade Technology Pte. Ltd.

Annexon, Inc.

4.00
-0.0100-0.25%
Post-market: 4.000.00000.00%19:30 EDT
Volume:3.21M
Turnover:12.78M
Market Cap:760.00M
PE:-3.55
High:4.04
Open:3.99
Low:3.86
Close:4.01
52wk High:7.18
52wk Low:2.54
Shares:190.00M
Float Shares:164.00M
Volume Ratio:0.97
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1271
EPS(LYR):-1.3445
ROE:-105.26%
ROA:-51.54%
PB:4.08
PE(LYR):-2.97

Loading ...

Annexon price target raised to $15 from $14 at JPMorgan

TIPRANKS
·
Sep 30

US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB

Reuters
·
Sep 30

Annexon Presents Phase 3 Archer II Baseline Data for Vonaprument Geographic Atrophy Trial at Retina Society Meeting

Reuters
·
Sep 24

Annexon Grants New Hires Options for 275,500 Shares at USD 3.92 Each

Reuters
·
Sep 17

Annexon Reports Inducement Grants to New Employees Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 17

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 17

Annexon CEO Love Joins Fireside Chats at September Investor Conferences

Reuters
·
Sep 02

Annexon price target raised to $14 from $10 at JPMorgan

TIPRANKS
·
Sep 01

U.S. Research Roundup-Autodesk, Hubspot, Oracle

Reuters
·
Sep 01

Annexon Biosciences Bets Big on Pivotal Trial Wins

TIPRANKS
·
Aug 27

Annexon Reports Inducement Grants to New Employees Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 18

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 18

Annexon participates in a conference call with JPMorgan

TIPRANKS
·
Aug 17

Jasper Therapeutics Q2 Loss Per Share Beats Estimates, Raises $132 Mln

Reuters
·
Aug 14

ProMIS Neurosciences Q2 Net Loss Widens

Reuters
·
Aug 14

Annexon Raised to Market Perform from Market Underperform by Citizens

Dow Jones
·
Aug 13

Annexon Files Form 3 as Director Mark S. Blumenkranz Reports no Beneficial Ownership

Reuters
·
Aug 13

Annexon, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Annexon: Strategic Phase 3 Trial Flexibility Supports Buy Rating and Unchanged $25 Price Target

TIPRANKS
·
Aug 12